Kairos Pharma, Ltd.
Kairos Pharma, Ltd. (KAPA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · KAPA · as of Jun 9, 2026
Key Statistics
Explore Kairos Pharma, Ltd. Data
kapa stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
kapa competitorsKAPA
ALLR
BCTX
CASI
CING
CLSDStock Performance
Full HistoryAbout Kairos Pharma, Ltd.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of an…
what is kairos pharma, ltd. · kapa stock overview · kairos pharma, ltd. company profile · who is kairos pharma, ltd. ceo · kapa AMEX · kairos pharma, ltd. headquarters · kairos pharma, ltd. business segments
About Stock Overview & Key Data
Kairos Pharma, Ltd. (KAPA) is a Healthcare company in the Biotechnology industry, listed on AMEX since Sep 16, 2024. As of the latest trading session, KAPA stock price is $0.45, with a market capitalization of $9.6M. The stock has returned -20.63% over the past 12 months and -36.62% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Kairos Pharma, Ltd. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Kairos Pharma, Ltd. reported revenue of — and net income of -$5.4M. For detailed data — including Kairos Pharma, Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Kairos Pharma, Ltd. (KAPA) stock price is $0.45. The stock is traded on AMEX under the ticker symbol KAPA. The 52-week range is $0.43 – $2.11.